Mon.Jan 01, 2024

article thumbnail

Magazine: Pharma’s path to Net Zero: Targeting Scope 3 emissions

Pharmaceutical Technology

In this issue: Pharma’s efforts to curb Scope 3 emissions, understanding European Pharmaceutical legislation, and looking back at the pharma industry’s performance in 2023.

246
246
article thumbnail

Popular Type 2 Diabetes And Weight Loss Drug May Protect Against Colorectal Cancer

AuroBlog - Aurous Healthcare Clinical Trials blog

A drug commonly used to treat type 2 diabetes could also effectively protect against colorectal cancer (CRC), based on a new analysis by researchers in the US. The drug in question is a class of medications known as glucagon-like peptide-1 receptor agonists – more easily referred to as GLP-1 RAs.

Drugs 190
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Lawsuit claims J&J illegally delayed Stelara biosimilars

pharmaphorum

A lawsuit in the US is accusing Johnson & Johnson of unlawfully delaying the onset of biosimilar competition to its immunology blockbuster Stelara beyond its US patent expiry date.

92
article thumbnail

Artificial intelligence in medical imaging revolutionizing diagnostics: Chandra Ganjoo

AuroBlog - Aurous Healthcare Clinical Trials blog

Medical imaging has revolutionized diagnostics with artificial intelligence (AI) providing the unprecedented accuracy for fast detection and personalized patient care. The year 2023 for India’s medtech industry characterized by resilience, innovation, provided push toward enhancing healthcare accessibility and quality amid global health challenges.

article thumbnail

European Clinical Supply Planning: Balancing Cost, Flexibility and Time

article thumbnail

Roche bolsters diagnostics with $295m LumiraDx deal

pharmaphorum

Roche has agreed a $295 million deal to buy a point-of-care diagnostics platform from LumiraDx, which recently went into administration

94
article thumbnail

FDA End-of-Year Release of Warning Letters Impresses (or Depresses)

FDA Law Blog

By Douglas B. Farquhar & Aisha T. Evans* & Irene Namata* — Primacy and recency are recognized psychological phenomena: people tend to remember the first thing they hear, and the last. It’s why litigators concentrate on their opening statement to a jury, and their closing argument. Maybe that’s also why FDA last week publicized the highest number of important Warning Letters of the year (compared with prior releases in 2023).

article thumbnail

Which pharmaceutical companies have the most drug patents in Ireland?

Drug Patent Watch

This chart shows the pharmaceutical companies with the most patents in Ireland. Patents must be filed in each country (or, in some cases regional patent office) where patent protection is… The post Which pharmaceutical companies have the most drug patents in Ireland? appeared first on DrugPatentWatch - Make Better Decisions.

Drugs 105